Kamgar F, Ho S, Hawe E, Brodtkorb TH. A review of treatment effect waning methods for immuno-oncology therapies in National Institute for Health and Care Excellence technology appraisals. Poster presented at the ISPOR Europe 2022; November 6, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S98. doi: 10.1016/j.jval.2022.09.476
Kamgar F, Thybo SH, Johannesen K, Teitsson S, Brodtkorb TH. Cost-effectiveness of nivolumab as an adjuvant treatment of muscle-invasive urothelial carcinoma at high risk of recurrence with tumor cell pd-l1 expression ≥ 1% in Denmark. Poster presented at the ISPOR Europe 2022; November 6, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S146. doi: 10.1016/j.jval.2022.09.706
Kamgar F, Johannesen K, Thybo SH, Teittson S, Brodtkorb TH. Cost-effectiveness of nivolumab for the adjuvant treatment of muscle-invasive urothelial carcinoma patients with high risk of recurrence and tumor cell pd-l1 expression ≥ 1% in Sweden. Poster presented at the ISPOR Europe 2022; November 6, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S146. doi: 10.1016/j.jval.2022.09.707
Oniangue-Ndza C, Kamgar F, Schneider RP, Teitsson S, Knight C. Cost-effectiveness of nivolumab as an adjuvant treatment of muscle-invasive urothelial carcinoma at high risk of recurrence in Switzerland. Poster presented at the ISPOR Europe 2022; November 6, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S146. doi: 10.1016/j.jval.2022.09.708
Yucel E, Hartley L, Bell J, Wolowacz S, Kamgar F, Hawe E. A systematic literature review of utility estimates for patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL). Poster presented at the ISPOR Europe 2022; November 6, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S395. doi: 10.1016/j.jval.2022.09.1964
Rothwell B, Sheikh K, Knight C, Kamgar F, Jain R, Mamtani R, Kurt M, Poretta T, Broughton E, Teitsson S. Cost-utility of Nivolumab versus observation for the adjuvant treatment of Urothelial Carcinoma (UC) for patients who are at high-risk of recurrence: a United States (US) payer perspective. Poster presented at the ISPOR 2022 Conference; May 15, 2022. Washington, DC. [abstract] Value Health. 2022 Jun;.
Kamgar F, Hughes R, Lucherini S. Developing a predictive algorithm to identify the key factors impacting on the transmission and fatalities from COVID-19. Value Health. 2021 Jun 1;24(Suppl 1):S114. doi: 10.1016/j.jval.2021.04.1237